Nanobiotix H1 FY26 net loss widens to €34.3 million; revenue and other operating income drops to €5.6 million

• Nanobiotix first-half 2026 revenue and other operating income fell 78.95% to EUR 5.6 million.
• Net loss attributable to ordinary shareholders widened to EUR 34.3 million, or EUR 0.70 per share.
• R&D expenses slipped to EUR 12.7 million, while SG&A costs edged down to EUR 10.8 million.
• Cash and cash equivalents climbed to EUR 110.9 million at June 30, extending financial runway through 2029.
• Laurent Levy cited encouraging JNJ-1900 (NBTXR3) data across indications and a Phase 3 NANORAY-312 protocol amendment to enable an earlier final readout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609241615OMX_____CNEWS_FR_GNW9833617_fr) on September 24, 2026, and is solely responsible for the information contained therein.